Gene · 5648
Papers2,041
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,041
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting the Roots of Kidney Disease: Systematic Review of the Therapies Targeting the Complement System. | Medicina (Kaunas) | 2025 | 40731834 | PubTator, text mining | PubMed |
| Nanostructured Protein Surfaces Inspired by Spider Silk. | Adv Mater | 2025 | 40722237 | PubTator, text mining | PubMed |
| Activation of the Complement/Lectin Pathway, Angiopoietin/Tie-2/VEGF-System, Cytokines and Chemokines in Different Angioedema Subtypes. | Eur J Immunol | 2025 | 40685762 | PubTator, text mining | PubMed |
| The 'autoimmunome' of centenarians. | J Transl Autoimmun | 2025 | 40546301 | PubTator, text mining | PubMed |
| Mass spectrometry-based discovery and diagnostic validation of T. cruzi antigens in the urine of congenitally infected Chagas Disease patients. | PLoS Negl Trop Dis | 2025 | 40523044 | PubTator, text mining | PubMed |
| MASP1 as a favorable prognostic biomarker in pediatric osteosarcoma: an integrated analysis of machine learning, bioinformatics, and validation experiments. | Transl Pediatr | 2025 | 40519720 | PubTator, text mining | PubMed |
| MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity. | Discov Oncol | 2025 | 40512453 | PubTator, text mining | PubMed |
| Ficolin-3 Activates Complement and Triggers Necroptosis in Cholangiocarcinoma Cells via the RIPK1/RIPK3/MLKL Signaling Pathway. | FASEB J | 2025 | 40407231 | PubTator, text mining | PubMed |
| Transcriptomic analysis of differential expression between surviving and nonsurviving patients infected by the SARS-CoV-2 Delta variant. | Sci Rep | 2025 | 40374692 | PubTator, text mining | PubMed |
| Effects of fish oil intervention on type 2 diabetes early risk novel biomarkers in healthy middle-aged and elderly adults: a double-blind randomized controlled trial. | Food Funct | 2025 | 40356575 | PubTator, text mining | PubMed |
| A chitosan-integrated antibacterial protein composite nanocomplex derived from barnacle cement and spider silk. | J Biotechnol | 2025 | 40348090 | PubTator, text mining | PubMed |
| Correlations of the Complement Proteins MASP-2 and MASP-3 With Clinical Severity and Short-Term Outcomes in Primary Membranous Nephropathy Patients. | Nephrology (Carlton) | 2025 | 40294883 | PubTator, text mining | PubMed |
| A novel 5-differentially expressed gene (DEG) signature predicting the prognosis in patients with metastatic liver malignancies and the prognostic and therapeutic potential of SPP1. | Int J Clin Oncol | 2025 | 40014188 | PubTator, text mining | PubMed |
| Corrigendum: Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs. | Front Immunol | 2025 | 40013135 | PubTator, text mining | PubMed |
| Small molecule inhibitors of mannan-binding lectin-associated serine Proteases-2 and-3. | Eur J Med Chem | 2025 | 40010268 | PubTator, text mining | PubMed |
| Plasma proteome variation and its genetic determinants in children and adolescents. | Nat Genet | 2025 | 39972214 | PubTator, text mining | PubMed |
| Complement proteins in axial spondyloarthritis: associations with disease activity and TNFi treatment response in a multicentre RCT. | Rheumatol Adv Pract | 2025 | 39959130 | PubTator, text mining | PubMed |
| Myosin Light Chain 12b and MASP1 as Novel Biomarker Candidates in Active Juvenile Idiopathic Arthritis─A Combined Proteomics/Bioinformatics Approach. | J Proteome Res | 2025 | 39932158 | PubTator, text mining | PubMed |
| Complement function and activation in human serum and plasma collected in different blood collection tubes. | J Immunol Methods | 2025 | 39921078 | PubTator, text mining | PubMed |
| MASP1 modulation as a novel therapeutic target in severe pediatric pertussis: insights from a multi-omics approach. | Infect Immun | 2025 | 39841046 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5648/papers?page=4